



Chiasma to Report Second Quarter 2020 Results on August 10

August 3, 2020

Company to host conference call and webcast at 5:00 p.m. ET

NEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2020 and to provide a business update.

Conference Call Details

Monday, August 10th @ 5pm Eastern Time

Domestic: 855-327-6837

International: 631-891-4304

Conference ID: 10010555

Webcast: <http://public.viavid.com/index.php?id=141033>

A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, <https://ir.chiasma.com/events-presentations>. An archived replay of the webcast will be available on the Company's website approximately two hours after the event. The archived webcast will be available for one year.

About Chiasma

Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE[®]) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company's website at www.chiasma.com.

Investor Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com

Media Relations:

Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com

